Skip to main content

Table 1 Baseline characteristics in 28 patients. Values are reported as frequency (n [%]) or as mean (range)

From: Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from China

CharacteristicNumber of patients (percent)
Age, yrs
  ≤ 5913 (46.4)
  > 5915 (53.6)
Primary tumor location
 Ovary26 (92.9)
 Fallopian tube2 (7.1)
 Peritoneum0 (0)
International FIGO stage
 I4 (14.3)
 II2 (7.1)
 III19 (67.9)
 IV3 (10.7)
Histological type
 Serous25 (89.3)
 Endometrioid1 (3.6)
 Mixed serous and endometrioid1 (3.6)
 Mixed serous and mucious1 (3.6)
Family history of cancer
 Yes10 (35.7)
 No15 (53.6)
 Missing data3 (10.7)
ECOG
 018 (64.3)
 110 (35.7)
BRCA
 BRCA 1/2 mutation11 (39.3)
 Wild type11 (39.3)
 Unknown6 (21.4)
Sensitivity to platinum-based chemotherapy
 Platinum-sensitive11 (39.3)
 Platinum-resistant13 (46.4)
 Unknown4 (14.3)
Categories of therapy
 First-line maintenance therapy2 (7.1)
 Second-line maintenance therapy10 (35.7)
 Treatment after multi-line chemotherapy6 (21.4)
 Exploratory therapy10 (35.7)
Primary cytoreductive surgery
 Yes27 (96.4)
 No1 (3.6)
Secondary cytoreductive surgery
 Yes6 (21.4)
 No22 (78.6)
Combination of anti-angiogenic agents
 Yes4 (14.3)
 No24 (85.7)
  1. Abbreviations: FIGO, International Federation of Gynecology and Obstetrics; ECOG, Eastern Cooperative Oncology Group